361546 | GSK-3β Peptide Inhibitor, Cell-permeable - Calbiochem

361546
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical Formula
      C₆₆H₁₁₀N₁₅O₂₀P

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      361546-1MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Plastic ampoule 1 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA cell-permeable myristoylated form of GSK-3β Peptide Inhibitor (Cat. No. 361545) with a glycine spacer. Acts as a selective, substrate-specific, competitive inhibitor of GSK-3β (IC50 = 40 µM). Does not affect the activities of Cdc2, PKB, and PKC. Shown to mimic insulin action, and activate glycogen synthase activity (~2.5-fold) in HEK293 cells and improve glucose tolerance in diabetic mice. Displays in vivo stability.
          Catalogue Number361546
          Brand Family Calbiochem®
          SynonymsL803-mts, Myr-N-GKEAPPAPPQSpP-NH₂
          References
          ReferencesPlotkin, B., et al. 2003. J. Pharmacol. Exp. Ther. 305, 974.
          Product Information
          ATP CompetitiveN
          DeclarationThis product is covered by one or more US patents and/or patent applications and foreign counter-parts owned by Tel Aviv University Future Technology LP, a limited partnership formed under the laws of Israel. Purchase of this product conveys a non-exclusive license to use the product for research purposes only. Purchase of this product does not convey the right to (i) incorporate or use the product in the manufacture of any commercial product, (ii) sell or otherwise transfer the product to any third party, or (iii) use the product to provide any commercial service. THE PRODUCT IS NOT FOR USE IN HUMANS. For information on purchasing a license to this product for purposes other than research, contact VP Business Development, Ramot at Tel Aviv University Ltd., Tel Aviv University, Licensor-Aviv, Tel Aviv 61392, Israel, Phone: +972 3 640 6608; Fax: +972 3 640 6675.
          FormLyophilized white solid
          FormulationSupplied as a trifluoroacetate salt.
          Hill FormulaC₆₆H₁₁₀N₁₅O₂₀P
          Chemical formulaC₆₆H₁₁₀N₁₅O₂₀P
          Hygroscopic Hygroscopic
          ReversibleN
          Applications
          Biological Information
          Primary TargetGsk-3β
          Primary Target IC<sub>50</sub>40 µM against Gsk-3β
          Purity≥98% by HPLC
          Physicochemical Information
          Cell permeableY
          Peptide SequenceMyr-N-Gly-Lys-Glu-Ala-Pro-Pro-Ala-Pro-Pro-Gln-Ser(PO₃H)-Pro-NH₂
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage -20°C
          Hygroscopic Hygroscopic
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          361546

          References

          Reference overview
          Plotkin, B., et al. 2003. J. Pharmacol. Exp. Ther. 305, 974.

          Brochure

          Title
          Alzheimer's Disease Brochure & Technical Guide
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision01-July-2008 RFH
          SynonymsL803-mts, Myr-N-GKEAPPAPPQSpP-NH₂
          DescriptionA cell-permeable myristoylated form of GSK-3β Peptide Inhibitor (Cat. No. 361545) with a glycine spacer. Acts as a selective, substrate-specific, competitive inhibitor of GSK-3β (IC50 = 40 µM). Does not affect the activities of Cdc-2, PKB, or PKC. Shown to mimic insulin action, and activate glycogen synthase activity (~ 2.5-fold) in HEK293 cells. Also reported to improve glucose tolerance in diabetic mice. Exhibits greater in vivo stability.
          FormLyophilized white solid
          FormulationSupplied as a trifluoroacetate salt.
          Intert gas (Yes/No) Packaged under inert gas
          Chemical formulaC₆₆H₁₁₀N₁₅O₂₀P
          Peptide SequenceMyr-N-Gly-Lys-Glu-Ala-Pro-Pro-Ala-Pro-Pro-Gln-Ser(PO₃H)-Pro-NH₂
          Purity≥98% by HPLC
          SolubilityDMSO (5 mg/ml) or CH₃CN:H₂O (1:1) (1 mg/ml)
          Storage -20°C
          Hygroscopic
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Toxicity Standard Handling
          ReferencesPlotkin, B., et al. 2003. J. Pharmacol. Exp. Ther. 305, 974.